EANS-News: CompuGroup Medical AG - First Quarter Results 2011
Geschrieben am 04-05-2011 |
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
quarterly report
Koblenz (euro adhoc) - May 4, 2011: CompuGroup Medical AG today
presented the financial report for the first quarter of 2011. The
company, one of the leading global providers of eHealth solutions,
achieved revenue of EUR 90.3 million, an increase of 30 percent
compared to the same period in 2010. Operating profit (EBITDA) came
in at EUR 14.0 million, up from EUR 12.6 million in the first quarter
last year. Cash net income increased 8 percent from EUR 7.5 million
in the first quarter 2010 to EUR 8.1 million in the first quarter
2011.
With this result, CompuGroup Medical AG continues its strategy and
growth based on the greatest coverage among healthcare providers
(physicians, dentists, hospitals etc.) worldwide. The strong 17
percent organic growth in the HCS (Health Connectivity Services)
business segment is a solid rebound from last year based on CGM´s
unique products and services to facilitate networking between various
healthcare participants. Newly acquired companies drive revenue
growth in the HPS (Health Provider Services) business segment up to
33 percent of which 5 percent is organic growth. A challenging start
to 2011 in the US is due to lower than expected efficiency in
acquired companies, and this leads to a decline in operating margin
which went from 18 percent during the first quarter of 2010 to 15
percent in the same period this year.
Frank Gotthardt, Chairman of the Board of CompuGroup Medical AG,
stated: "We are certainly excited about the solid performance in
European markets and especially pleased with the rebound in HCS
revenue. With the consolidation and restructuring of the US business
now about to be completed we are confident to bring CompuGroup
Medical to a new level of growth and profitability in the second half
of 2011."
CompuGroup Medical adjusts the full year 2011 guidance to reflect the
development in the US. Group revenue is expected to be in the range
of EUR 385 million to EUR 410 million and operating income (EBITDA)
is expected to be in the range of EUR 81 million to EUR 88 million.
Conference Call for Journalists, Investors and Analysts: The
management board of CompuGroup Medical AG will go through the Q1
results at a conference call for analysts and investors today at
15:00 hours CEST.
You can participate in this conference call by dialing one of the
following phone numbers: +49 69 210869703 (Germany) +44 16 16018902
(UK) +1 2153054495 (USA) Participant code: 18561270
At the beginning of the conference call, a presentation will be made
available for download on the CompuGroup Medical website at
www.cgm.com. The presentation can be viewed live at
https://compugroup.webex.com.
About CompuGroup Medical AG
CompuGroup Medical is one of the leading eHealth companies in the
world. Its software products are designed to support all medical and
organizational activities in doctors´ offices and hospitals. Its
information services for all parties involved in the healthcare
system and its web-based personal health records contribute towards
safer and more efficient healthcare. CompuGroup Medical´s services
are based on a unique customer base of over 380,000 doctors,
dentists, hospitals and networks as well as other service providers.
CompuGroup Medical is the eHealth company with one of the highest
coverage among eHealth service providers worldwide. Approximately
3300 highly qualified employees in 25 countries support customers
with innovative solutions for the steadily growing demands of the
healthcare system.
end of announcement euro adhoc
--------------------------------------------------------------------------------
ots Originaltext: CompuGroup Medical AG
Im Internet recherchierbar: http://www.presseportal.de
Further inquiry note:
CompuGroup Medical AG
Barbara Müller
Consultant Press & Media
P +49 (0) 261 8000-1293
F +49 (0) 261 8000-3284
E-Mail: press@cgm.com
Branche: Software
ISIN: DE0005437305
WKN: 543730
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade
Kontaktinformationen:
Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.
Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.
Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.
http://www.bankkaufmann.com/topics.html
Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.
@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf
E-Mail: media(at)at-symbol.de
329636
weitere Artikel:
- EANS-Adhoc: WINCOR NIXDORF Aktiengesellschaft / Markterholung nicht tragfähig
genug: Wincor Nixdorf senkt Prognose und beschließt zugleich
Aktienrückkaufprogramm --------------------------------------------------------------------------------
Ad-hoc-Meldung nach § 15 WpHG übermittelt durch euro adhoc mit dem Ziel
einer europaweiten Verbreitung. Für den Inhalt ist der Emittent
verantwortlich.
--------------------------------------------------------------------------------
6-Monatsbericht
04.05.2011
Die Wincor Nixdorf AG senkt infolge der nicht durchgängigen
Markterholung sowie noch nicht im geplanten Umfang realisierbarer
Umsatz- und Ergebnisbeiträge im Geschäft mit High-End-Systemen mehr...
- EANS-Adhoc: WINCOR NIXDORF Aktiengesellschaft / Market recovery lacks solidity:
Wincor Nixdorf lowers forecast and agrees share buyback program --------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
6-month report
04.05.2011
Against the backdrop of inconsistent market recovery and in view of
the fact that planned net sales and earnings contributions from
business with mehr...
- EANS-News: Henkel AG & Co. KGaA / Henkel reports solid start to fiscal 2011 --------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
quarterly report/3-month report/Henkel
Düsseldorf (euro adhoc) - May 4, 2011
Henkel expects stronger organic sales growth
Henkel reports solid start to fiscal 2011
• Sales increase of 8.9 percent to 3,823 million euros (organic: +7.2%)
• mehr...
- EANS-Adhoc: Intercell AG / Intercell starts clinical trial in Pandemic Influenza
with its Vaccine Enhancement Patch and provides update to the strategic
collaboration with GSK on patches --------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------
Research & Development
04.05.2011
» Intercell starts a confirmatory clinical study using the Vaccine
Enhancement Patch in combination with GSK's H5N1 pandemic
Influenza antigen » GSK and Intercell underline mehr...
- EANS-Adhoc: Intercell AG / Intercell startet klinische Studie für das
immunstimmulierende Impfpflaster gegen pandemische Grippe und berichtet über
aktuellen Stand der strategischen Allianz mit GSK im --------------------------------------------------------------------------------
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer
europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich.
--------------------------------------------------------------------------------
Forschung/Entwicklung
04.05.2011
» Intercell startet eine bestätigende, klinische Studie des
immunstimmulierenden Impfpflasters "Vaccine Enhancement Patch" (VEP)
in Kombination mit dem pandemischen Influenza Antigen H5N1 von mehr...
|
|
|
Mehr zu dem Thema Finanzen
Der meistgelesene Artikel zu dem Thema:
Century Casinos wurde in Russell 2000 Index aufgenommen
durchschnittliche Punktzahl: 0 Stimmen: 0
|